INNOVATIVE KEYS TO
HEALTH AND WELLBEING
NEWS
  • June 2017: Poster Presentation at ANZCHOG 2017
  • Innokeys | June 20th, 2017
  • Adelaide, South Australia (June 20, 2017) – Innokeys Pte Ltd attended ANZCHOG 2017 - a conference which is organized annually by the Australian and New Zealand Children's Haematology/Oncology Group (ANZCHOG). Dr Normando Iznaga-Escobar, the Scientific Officer of Innokeys Pte Ltd, attended ANZCHOG 2017 to present a poster summarizing 10 years of experience with the use of nimotuzumab, an anti-EGFR humanized monoclonal antibody, for the treatment of newly diagnosed children with Diffuse I...
  • July 2015: Innokeys Pte Ltd Consolidates Nimotuzumab Development by Acquiring Oncoscience AG
  • Innokeys | September 22nd, 2015
  • Innokeys Pte Ltd Consolidates Nimotuzumab Development by Acquiring Oncoscience AG • The acquisition enables Innokeys to fully lead clinical and commercial development of Nimotuzumab in Europe • Transaction will accelerate the commercial route of Nimotuzumab Singapore, July 22, 2015—Innokeys Pte. Ltd today announced the acquisition of Oncoscience AG, a privately held Germany biotechnology company focused on oncology. The successful acquisition of all outstanding capital s...
  • August 2015: Innokeys Pte Ltd attends Congress of Obstetrics and Gynecology Indonesia 2015
  • Innokeys | August 26th, 2015
  • Innokeys Pte Ltd attends Congress of Obstetrics and Gynecology Indonesia 2015 Bandung, Indonesia (Augus 26, 2015) – Innokeys Pte Ltd attended the Congress of Obstetrics and Gynecology Indonesia and had the opportunity to create awareness for Bacterial Vaginosis and Vaginal Atrophy. In line with its awareness creation activities Innokeys also presented information on its upcoming products Regelle and Relactagel. The Innokeys representatives received a lot of positive feedback from cong...
  • May 2015 : Innokeys Pte Ltd at Asia Biotech Invest 2015
  • Innokeys | June 18th, 2015
  • Kowloon, Hong Kong (May 20, 2015) – Innokeys Pte Ltd attended the Asia Biotech Invest 2015 as one of the presenting companies. In total Asia Biotech Invest 2015 welcomed 22 biotech companies from around the world to present their R&D pipeline and investment memorandums. Dr. Rikrik Ilyas, CEO of Innokeys Pte Ltd, presentation covered Innokey’s product pipeline, current and future development opportunities, including plans for an upcoming expansion. About the Event Asia Biotech...
  • August 2013: Nimotuzumab in MOGA Australia
  • Innokeys | December 6th, 2013
  • Medical Oncology Group of Australia...
  • ASCO 2013 : Nimotuzumab Abstracts
  • Innokeys | December 6th, 2013
  • Professor Dirk Strumberg from Germany (center, in blue suit), the principal investigator of phase IIB/IIIA nimotuzumab clinical trial on pancreatic cancer, in discussion with Ferdinand Bach, CEO of Oncoscience AG, the sponsor of the trial, as the other ASCO participants viewed the Poster during the poster session. 1. Pancreas. Phase II, randomized, double-blind placebo-controlled trial of nimotuzumab plus gemcitabine compared with gemcitabine alone in patients (pts) with advanced p...
  • Daiichi Sankyo Enrolls First Patient in Nimotuzumab Phase 3 Clinical Trials
  • Innokeys | December 6th, 2013
  • Tokyo, Japan (April 25, 2013) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced today that the first patient has been enrolled in two pivotal phase 3 clinical trials of nimotuzumab (DE-766), a recombinant humanized monoclonal antibody targeting the Epidermal Growth Factor Receptor (EGFR), which is being evaluated for the treatment of patients diagnosed with lung cancer and with gastric cancer.   About Phase 3 Clinical Trials for Lung Cancer The phase 3 ...
  • YM BioSciences Reports Divestiture of Nimotuzumab Assets by CIMYM
  • Innokeys | January 4th, 2013
  • MISSISSAUGA, ON, Dec. 3, 2012 /PRNewswire/ - YM BioSciences Inc. (NYSE MKT: YMI, TSX: YM) today reported that CIMYM BioSciences Inc. has sold its assets relating to nimotuzumab to InnoKeys PTE Ltd., a company based in Singapore, for undisclosed consideration including an immediate US$2 million payment. CIMYM was a joint venture subsidiary 80% owned by YM BioSciences and 20% owned by CIMAB S.A.(representing Centro de Inmunología Molecular, Cuba). CIMAB S.A. has reported it h...